Compare BridgeBio Pharma Inc (BBIO) vs YieldMax AI & Tech Portfolio Option Income ETF (GPTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs YieldMax AI & Tech Portfolio Option Income ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while YieldMax AI & Tech Portfolio Option Income ETF trades at $42.5. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, YieldMax AI & Tech Portfolio Option Income ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | GPTY | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $90.17 | $50.52 |
52-Week Low | $47.29 | $34.73 |
Enterprise Value | $18.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
GPTY trades at $42.64, up 0.94% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on AI and tech equities, using options strategies to generate weekly dividends, with recent payouts ranging from $0.28 to $0.37. Support and resistance levels are clustered around $41-$43, indicating tight trading ranges.
Outlook is supported by AI theme momentum and income generation, but risks include semiconductor concentration and NAV erosion from options strategies. Investor sentiment is mixed, with some analysts highlighting yield sustainability concerns versus exposure benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →
